Conference Proceedings
AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM)
Mark A Rosenthal, Carmen Balana, Myra E van Linde, Cyrus Sayehli, Walter M Fiedler, Martin Wermke, Christophe Massard, Ingo K Mellinghoff, Mustafa Khasraw, Agnes Ang, Erik Rasmussen, Johannes Kast, Sabine Stienen, Timothy F Cloughesy
NEURO-ONCOLOGY | OXFORD UNIV PRESS INC | Published : 2019
Abstract
Abstract OBJECTIVES The class III variant of the epidermal growth factor receptor (EGFRvIII) represents the most common EGFR mutation in GBM. AMG 596 is a bispecific T cell engager (BiTE®) molecule designed to engage a patient’s own CD3-positive T cells to EGFRvIII-positive tumor antigens. This is the first clinical data readout for AMG 596. METHODS This phase 1, first-in-human, open-label, sequential dose-escalation/expansion study evaluates continuous intravenous AMG 596 in patients with EGFRvIII-positive GBM or malignant glioma in recurrent (Group 1) or newly diagnosed i..
View full abstract